NCT00658684 - Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder. | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Overactive Bladder

Interventions

DRUG

fesoterodine fumarate

4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks

Trial Locations (12)

Pfizer Investigational Site, Inegeku, Chibashi

Pfizer Investigational Site, Akashi-shi

Pfizer Investigational Site, Amagasaki-shi

Pfizer Investigational Site, Chuou-ku, Koube-shi

Pfizer Investigational Site, Kaibara-cho, Tanba-shi

Pfizer Investigational Site, Nishinomiya-shi

Pfizer Investigational Site, Kawasakishi

Pfizer Investigational Site, Sagamihara-shi

Pfizer Investigational Site, Nara

Pfizer Investigational Site, Osaka

Pfizer Investigational Site, Edogawa-ku

Pfizer Investigational Site, Shibuya-ku